Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB056 prophylactic sublingual spray for angina burden in symptomatic coronary artery disease
2026-525239-17-00Phase 2Withdrawn
- Sponsor
- Pohl-Boskamp
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitroglycerin and Placebo-COD Research Private Ltd in coronary arteriosclerosis and angina pectoris (2 arms), sponsored by Pohl-Boskamp. Primary endpoint: SAQ-7 summary score at Week 8. Planned start Oct 2026; status: withdrawn.
02
Drugs
nitroglycerinPlacebo-COD Research Private Ltd
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on 2026-525239-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525239-17-00.